Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

724 ARTÍCULOS , VIENDO DEL 511 AL 525

Reliability and validity of the Vietnamese version of the Montreal Cognitive Assessment in Parkinson's disease

Tran HT, Huynh MBT.

Rev Neurol (Paris). 2026 Mar;182(3):175-185. doi: 10.1016/j.neurol.2026.01.003. Epub 2026 Feb 3.

EEG Microstates Are Associated with Motor Function in Parkinson's Disease: A Cross-Sectional Observational Study

Cai J, Zhao Y, Song J, Xu X, Xu J, Shi H, Wei W, Xue X.

Brain Behav. 2026 Jan;16(1):e71151. doi: 10.1002/brb3.71151.

Intermittent Theta-Burst Stimulation for Depressive Symptoms in Parkinson Disease: A Randomized Clinical Trial

Hou M, Tian B, Qi C, Song L, Ma B, Chen X, Wan Y, Wu N, Gan J, Liu Z, Zhang Y.

JAMA Netw Open. 2026 May 1;9(5):e2613580. doi: 10.1001/jamanetworkopen.2026.13580.

Comprehensive effects of Parkinson's disease multimodal complex treatment (PD-MCT): a two-center prospective trial

Friedrich I, Gutschow L, Weise D, Rumpf JJ, Classen J, Fricke C.

J Neurol. 2026 Feb 18;273(2):150. doi: 10.1007/s00415-026-13697-1.

[Clinical practice guideline for integrated PET/MRI in Parkinson's disease (2026 edition)]

Chinese Society of Medical Imaging Technology; Chinese Society of Radiology; Chinese Society of Nuclear Medicine; Beijing Society of Nuclear Medicine; Beijing Society of Radiology.

Zhonghua Yi Xue Za Zhi. 2026 Apr 28;106(16):1541-1554. doi: 10.3760/cma.j.cn112137-20251222-03386.

The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease

Werner MH, McGarry A, Meyer C, Mancino E, Klint C, Pellecchia J, Kieburtz K, Levine T, Bellaire B, Gibbons C, Freeman R, Ellenbogen A, Klos K, Ospina M, Hauser RA, Shannon K, Asaad H, Park A, McAllister P, Isaacson SH, LeDoux MS, Dhall R, Shpiner D, Charles P, Agarwal P, Peckham E, Mazzeo P, Davis M, Pahwa R, Brodsky M, Lew M, Purino L, Mantri S, Parashos S, Justiz W, Chachar M, Robottom B, Budman E, Blindauer K, Bellows S, Goudreau J, Steen S, Olanow CW.

Nat Aging. 2026 Mar;6(3):626-635. doi: 10.1038/s43587-026-01084-4. Epub 2026 Feb 20.

The interplay between GBA1 status and age of onset on cognitive, motor and non-motor outcomes in Parkinson's disease: multicenter cross-sectional study

Ledda C, Gallo S, Avenali M, Artusi CA, Imbalzano G, Donetto F, Montanaro E, Romagnolo A, Mitrotti P, Gallo L, De Micco R, Sant'Elia V, Siciliano M, Tessitore A, Calandra-Buonaura G, Giannini G, Sambati L, Lopiano L, Valente EM, Bozzali M.

J Neurol. 2026 Feb 1;273(2):111. doi: 10.1007/s00415-026-13639-x.

Real-world outcomes and early discontinuation of foslevodopa/foscarbidopa in Parkinson's disease

Tsuboi T, Kimura K, Ikenaka K, Baba T, Matsuura K, Kajiyama Y, Kamiyama D, Uematsu T, Abe K, Kakuda K, Takenaka H, Miyashita K, Saito A, Mihara M, Shindo A, Hasegawa T, Kimura Y, Tanaka F, Hattori N, Katsuno M, Nishikawa N.

J Neurol. 2026 May 19;273(6):320. doi: 10.1007/s00415-026-13879-x.

Transcranial Magnetic Stimulation in Parkinson's Disease and Parkinsonian Syndromes: A Narrative Expert Review

Cantone M, Pennisi M, Bella R, Ferri R, Fisicaro F, Lanza G, Mogavero MP, Palmigiano A, Quercia A, Zappia M.

Life (Basel). 2026 Feb 1;16(2):233. doi: 10.3390/life16020233.

Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's disease

Toffoli M, Menozzi E, Cullen M, Chowdhury K, Ahmed S, Freemantle N, Duffen J, Wyse RK, Stott SRW, Matthews H, Dexter D, Ikeji F, Moss J, Watts P, Foltynie T, Kieburtz K, Rascol O, Poewe W, Schapira AHV.

J Neurol. 2026 Feb 18;273(2):151. doi: 10.1007/s00415-026-13683-7.

Clinical features of adolescent-onset functional motor disorders in tertiary movement disorders centers

Geroin C, Ercoli T, Marcuzzo E, Sandri A, Camozzi S, Maddaloni D, Romito LM, Eleopra R, Tesolin L, Pellegrin S, Nicoletti A, Mostile G, Magliozzi A, Pilotto A, Modugno N, Olivola E, Demartini B, Nisticò V, Erro R, Cuoco S, Tessitore A, De Micco R, Ceravolo R, Del Prete E, Dallocchio C, Arbasino C, Esposito M, Assunta T, Bono F, Pascarella A, Petracca M, Zinzi P, Fabbrini G, Ferrazzano G, Bonanni L, Varanese S, Albanese A, Polverino P, Baglioni V, Defazio G, Zibetti M, Manganotti P, Solla P, Calandra-Buonaura G, Pisani A, Tinazzi M.

J Neurol. 2026 Mar 22;273(4):223. doi: 10.1007/s00415-026-13761-w.

Genetic Landscape of Monogenic Parkinson's Disease in the African Population-A Systematic Review

Banjaw Z, Assefa Z, Bogaert E, Crosiers D, Santens P, Dermaut B.

Mov Disord. 2026 Apr 9. doi: 10.1002/mds.70302. Online ahead of print.

Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation

Leong IL, Ng TH, Sen K, Burchill E, Costello H, Badenoch JB, Coebergh J, McCutcheon RA, Nair A, Browning M, Huys QJM, Lewis G, Lees A, David AS, Rogers JP.

Brain. 2026 Jan 8;149(1):18-36. doi: 10.1093/brain/awaf335.

AI-driven speech biomarkers for disease diagnosis and monitoring: a systematic review and meta-analysis

Yang Y, Zhao X, Zhao P, Ying D, Wang J, Jiang Y, Wan Q.

BMJ Evid Based Med. 2026 Jan 21;31(1):46-56. doi: 10.1136/bmjebm-2025-113759.

Hearing Loss in Parkinson's Disease: A Systematic Review and Meta-Analysis

Rajai Firouzabadi S, Mohammadi I, Golsorkh H, Mahdavi S, Sadeghzadeh S, Rezaei K, Salari M.

Mov Disord. 2026 May;41(5):1069-1080. doi: 10.1002/mds.70206. Epub 2026 Jan 30.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias